Alphabet Inc. drew a fresh wave of bullish calls after several Wall Street banks lifted their price targets in the space of 24 hours, citing stronger generative-AI monetization and steady search advertising trends ahead of the companyโs second-quarter earnings report expected next week. Morgan Stanley led the revisions on 21 July, boosting its target to $205 from $185 while reaffirming an Overweight rating. The bank said Alphabetโs โaccelerating pace of innovationโ and clearer disclosures around artificial-intelligence products should support faster revenue growth. Alphabet shares gained roughly 2.4% following the note. The momentum continued on 22 July when Scotiabank raised its target to $240 from $200 and kept a Sector Outperform stance, pointing to search momentum, AI adoption and YouTube strength. Stifel followed with a new $218 target and a Buy recommendation, while Wolfe Research and Raymond James reiterated their bullish views at $190 and $185, respectively. The cluster of upgrades highlights rising investor confidence that Alphabetโs expanded AI toolkitโspanning Search, Ads, Cloud and Workspaceโwill translate into higher top-line and earnings growth. Consensus forecasts currently look for the company to post double-digit revenue and earnings gains for the June quarter.
$NSC -Baird raises Norfolk Southern target to $300 from $255 Neutral - $NVAX -Bank of America lowers Novavax target to $9 from $10 Neutral - $NXPI -Needham raises NXP Semiconductors target to $250 from $225 Buy -Barclays raises target to $220 from $190 Overweight -
$FANG -Raymond James raises Diamondback Energy target to $221 from $204 Strong Buy - $GAP -Goldman lowers GAP target to $26 from $28 Buy - $HCM -Bank of America raises HUTCHMED target to $28 from $27 Buy - $KRYS -Bank of America trims Krystal Biotech target to $192 from $193 Buy
$DVN -Raymond James raises Devon Energy target to $45 from $40 Outperform - $EA -Wedbush reissues Electronic Arts $210 target Outperform - $ELV -JPMorgan lowers Elevance Health target to $34 from $472 Overweight - $EXEL -Morgan Stanley raises Exelixis target to $48 from $47